Document:

Form of 2004 Director Stock Plan

 EXHIBIT 10.4 
  
  
 XENOGEN CORPORATION 
  
 2004 DIRECTOR STOCK PLAN 
  
 1. Purposes of the Plan. The purposes of this 2004 Director Stock Plan
are to attract and retain the best available personnel for service as Outside Directors (as defined herein) of the Company, to provide additional incentive to the Outside Directors of the Company to serve as Directors, and to encourage their
continued service on the Board. 
  
 2. Definitions. As used
herein, the following definitions will apply: 
  
 (a) “Administrator” means the Board or any of its Committees as will be administering the Plan in accordance with Section 4 hereof. 
  

(b) “Annual Meeting” means the Company’s annual meeting of stockholders. 
  
 (c) “Applicable Laws” means the
requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the
applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan. 
  
 (d) “Award” means an award of Restricted Stock granted hereunder. 
  
 (e) “Board” means the Board of Directors of
the Company. 
  
 (f) “Change in
Control” means the occurrence of any of the following events: 
  
 (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of
securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities; or 
  
 (ii) The consummation of the sale or disposition by the Company of all or substantially all of the
Company’s assets; or 
  
 (iii) The
consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity
or its parent outstanding immediately after such merger or consolidation. 

 (g) “Code” means the Internal Revenue Code of 1986, as amended. Any
reference to a section of the Code herein will be a reference to any successor or amended section of the Code. 
  
 (h) “Common Stock” means the common stock of the Company, par value $0.001 per share. 
  
 (i) “Company” means Xenogen Corporation, a
Delaware corporation. 
  
 (j)
“Director” means a member of the Board. 
  
 (k) “Disability” means total and permanent disability as defined in Section 22(e)(3) of the Code. 
  
 (l) “Employee” means any person, including officers and Directors, employed by the Company or any Parent or Subsidiary of
the Company. The payment of a Director’s fee by the Company will not be sufficient in and of itself to constitute “employment” by the Company. 
  

(m) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
  
 (n) “Fair Market Value” means, as of any
date, the value of Common Stock determined as follows: 
  
 (i) If the Common Stock is listed on any established stock exchange or a national market system, including without limitation the Nasdaq Stock Market or The Nasdaq SmallCap Market of The Nasdaq Stock Market, its Fair Market Value will be
the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system for the day of determination as reported in The Wall Street Journal or such other source as the Administrator deems
reliable; 
  
 (ii) If the Common Stock is
regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a Share of Common Stock will be the mean between the high bid and low asked prices for the Common Stock for the day of determination, as
reported in The Wall Street Journal or such other source as the Administrator deems reliable; or 
  
 (iii) For purposes of any Awards granted on the Registration Date, the Fair Market Value will be the initial price to the public as set
forth in the final prospectus included within the registration statement in Form S-1 filed with the Securities and Exchange Commission for the initial public offering of the Company’s Common Stock; or 
  
 (iv) In the absence of an established market for the Common
Stock, the Fair Market Value thereof will be determined in good faith by the Administrator. 
  
 (o) “Inside Director” means a Director who is an Employee. 
  

 2 

 (p) “Outside Director” means a Director who has not been an Employee.

  
 (q) “Parent” means a
“parent corporation,” whether now or hereafter existing, as defined in Section 424(e) of the Code. 
  
 (r) “Plan” means this 2004 Director Stock Plan. 
  
 (s) “Registration Date” means the effective date of the first registration statement that
is filed by the Company and declared effective pursuant to Section 12(g) of the Exchange Act, with respect to any class of the Company’s securities. 
  
 (t) “Restricted Stock” means a grant of Shares subject to a forfeiture restriction that lapses over time. 
  
 (u) “Share” means a share of the Common
Stock, as adjusted in accordance with Section 9 of the Plan. 
  
 (v) “Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing, as defined in Section 424(f) of the Code. 
  

	 	3.	Stock Subject to the Plan. 

  
 (a) Plan Pool. Subject to the provisions of Section 9 of the Plan, the maximum aggregate number of Shares which may be granted
pursuant to Awards under the Plan is 150,000 Shares plus an annual increase to be added on the first day of the Company’s fiscal year beginning in 2005, equal to the lesser of (i) the number of Shares granted pursuant to Awards under the Plan
in the prior fiscal year or (ii) an amount determined by the Board (the “Pool”). The Shares may be authorized, but unissued, or reacquired Common Stock. 
  
 (b) Shares Returned to Pool. Unless the Plan has previously been terminated, unvested Shares of
Restricted Stock that are forfeited to the Company will be returned to the Pool and will be available for future grant under the Plan: 
  

	 	4.	Awards Generally. 

  
 (a) Limitations. Awards may be granted only to Outside Directors. All grants of Awards hereunder will be automatic and
nondiscretionary and will be made strictly in accordance with the terms set forth in Section 5. The Plan will not confer upon any grantee any right with respect to continuation of service as a Director or nomination to serve as a Director, nor will
it interfere in any way with any rights which the Director or the Company may have to terminate the Director’s relationship with the Company at any time. In the event that any Award granted under the Plan would cause the number of Shares
subject to outstanding Awards plus the number of Shares previously issued pursuant to an Award, then the remaining Shares available for award grant will be allocated on a pro rata basis. No further grants will be made until such time, if any, as
additional Shares become available for grant under the Plan through action of the Board or the stockholders to increase the number of Shares which may be issued under the Plan, 
  

 3 

 through an automatic Pool increase pursuant to Section 3 or through the forfeiture of Shares issued
pursuant to Awards previously granted hereunder. 
  
 (b) Stockholder Approval. Notwithstanding the provisions of Sections 5 hereof, any vesting of Restricted Stock granted before the Company has obtained stockholder approval of the Plan in accordance with Section 15 hereof will be
conditioned upon obtaining such stockholder approval. 
  
 (c) Other Committees. The Administrator will determine from time to time whether other service by Directors on committees of the Board not covered by the Plan warrants grants of Awards for such service, and will have the power and
authority to modify the Plan from time to time to establish non-discretionary, automatic award grants to be made to such committee members on such terms and at such times as the Administrator will determine. 
  
 (d) Deferral. Directors may, at their election, and
subject to rules and procedures implemented by the Administrator and Applicable Laws, defer the receipt of Shares otherwise deliverable hereunder upon the vesting of Restricted Stock. 
  

	 	5.	Restricted Stock. 

  
 (a) Initial Board Grant. Each Outside Director, or, if an Outside Director so directs the Company, such Outside Director’s
associated venture entity, will be automatically granted a number of Shares of Restricted Stock on the date on which the later of the following events occurs: 
  

(i) the date one (1) business day following the Registration Date; or 
  
 (ii) the date on which such person first becomes an Outside Director, whether through election by the
stockholders of the Company or appointment by the Board to fill a vacancy; provided, however, that an Inside Director who ceases to be an Inside Director but who remains a Director will not receive this initial Award; 
  
 This initial Award will equal a number of Shares of Restricted Stock determined by dividing
(A) $40,000 by (B) the Fair Market Value of a Share on the date of grant, with the number of Shares rounded up to the nearest whole Share. 
  
 Any request by an Outside Director to have this initial Award granted to his or her associated venture entity must be received by the Company in writing
prior to the date such initial Award is to be granted. 
  
 (b) Annual Board Grant. Upon each Annual Meeting, each Outside Director will be automatically granted a number of Shares of Restricted Stock determined by dividing (A) $40,000 by (B) the Fair Market Value of a Share on the date of
grant, with the number of Shares rounded up to the nearest whole Share, provided he or she is then an Outside Director; provided, however, that on the date of an Annual Meeting, each Outside Director who was not an Outside Director on
or before the Registration Date (for grants to be made on the date of the 2005 Annual Meeting) or the previous year’s Annual Meeting (for grants to be made after the 2005 Annual Meeting) will be automatically granted a pro-rated annual Award
calculated according to the number of quarters of service provided by such Outside Director since the Registration Date or the previous year’s Annual Meeting, as applicable. For purposes of the foregoing calculation, service for only a portion
of the quarter will be deemed service for the whole quarter. 
  
 Any request by an Outside Director to have this annual Award granted to his or her associated venture entity must be received by the Company in writing prior to the date such annual Award is to be granted. An Outside Director’s request
to have the annual Award granted to his or her associated venture entity will remain in effect for successive annual Awards, unless the Outside Director notifies the Company in writing that such request is withdrawn. Following the Company’s
receipt of such notice, all future annual Awards will be granted to the Outside Director, unless the Outside Director makes a subsequent written request to the Company that future annual Awards are to be granted to the Outside Director’s
associated venture entity. 
  

 4 

 (c) Forfeiture. Unless the Administrator determines otherwise, upon the voluntary
or involuntary termination of a grantee’s service as a Director for any reason (including death or Disability) before all of the Shares of Restricted Stock have vested in the manner set forth in Section 5(d), all such unvested Shares will
thereupon be forfeited and automatically transferred to and reacquired by the Company at no cost to the Company. Upon any such termination, the Company will become the legal and beneficial owner of the Shares of Restricted Stock being forfeited and
reacquired by the Company and all rights and interests therein or relating thereto, and the Company will have the right to retain and transfer to its own name the number of Shares of Restricted Stock being reacquired by the Company. 
  
 (d) Vesting. Subject to Section 11 hereof, each Award
of Restricted Stock granted hereunder will vest as to 100% of the Shares subject to such Award on the first anniversary of its date of grant (except as to the Award of Restricted Stock to be made pursuant to section 5(a)(i), which will vest on the
one-year anniversary of the Registration Date), provided that the grantee continues to serve as a Director through such date. 
  
 (e) Purchase Price. The purchase price per Share of Restricted Stock for each Award granted hereunder will be the par value of
$0.001 per Share. 
  
 6. Term of Plan. The Plan will
become effective upon the earlier to occur of its adoption by the Board or its approval by the stockholders of the Company as described in Section 15 of the Plan. It will continue in effect until terminated under Section 10. 
  
 7. Form of Consideration. The consideration to be paid for
Shares pursuant to an Award of Restricted Stock will consist of (i) cash, (ii) check, (iii) past services rendered to the Company, or (iv) such other consideration and method of payment for the issuance of Shares as the Administrator may determine
and to the extent permitted by Applicable Laws. 
  
 8.
Transferability. Unless the Administrator determines otherwise, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be
exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate. 
  
 9. Adjustments , Dissolution, Merger or Asset Sale. 

  
 (a) Adjustments. In the event that any
dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or
exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Board, in order to prevent diminution or enlargement of the benefits or potential benefits intended to
be made available under the Plan, may (in its sole discretion) adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares covered by each outstanding Award, and the number of Shares
issuable pursuant to Awards of Restricted Stock to be granted under Section 5. 
  

 5 

 (b) Dissolution or Liquidation. In the event of the proposed dissolution or
liquidation of the Company, to the extent that an Award has not been previously exercised, it will terminate immediately prior to the consummation of such proposed action. 
  
 (c) Change in Control. In the event of a Change in Control, each outstanding Award will be assumed or
an equivalent right substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the Award, all Shares of Restricted Stock will vest
and all restrictions with respect to such Shares will lapse. 
  
 For the purposes of this subsection (c), an Award will be considered assumed if, following the Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately
prior to the Change in Control, the consideration (whether stock, cash, or other securities or property), the fair market value of the consideration received in the merger or Change in Control by holders of Common Stock for each Share held on the
effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares). 
  
 With respect to Awards that are assumed or substituted for, if on the date of or following such assumption
or substitution the grantee’s status as a Director or a director of the successor corporation, as applicable, is terminated other than upon a voluntary resignation by the grantee, then all Shares of Restricted Stock will vest and all
restrictions with respect to such Shares will lapse. 
  
 10.
Amendment and Termination of the Plan. The Administrator may at any time amend, alter, suspend, or discontinue the Plan, but no amendment, alteration, suspension, or discontinuation will be made which would impair the rights of any
grantee under any grant theretofore made, without his or her consent. In addition, to the extent necessary and desirable to comply with any Applicable Law, the Company will obtain stockholder approval of any Plan amendment in such a manner and to
such a degree as required. Any such amendment or termination of the Plan will not affect Awards already granted and such Awards will remain in full force and effect as if this Plan had not been amended or terminated, unless a grantee otherwise
agrees in writing. 
  
 11. Time of Granting Awards. The
date of grant of an Award will, for all purposes, be the date determined in accordance with Sections 5 hereof. 
  
 12. Conditions on Issuance of Shares. Shares will not be issued under any Award unless the issuance and delivery of such Shares pursuant
thereto, and in the case of an Option, the exercise of such Option, will comply with all relevant provisions of law, including, without limitation, the Securities Act of 1933, as amended, the Exchange Act, the rules and regulations promulgated
thereunder, state securities laws, and the requirements of any stock exchange upon which the Shares may then be listed, and will be further subject to the approval of counsel for the Company with respect to such compliance. Inability of the Company
to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Company 
  

 6 

 of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority will not
have been obtained. The Company has no obligation to register any Shares issued pursuant to this Plan under the securities laws of any jurisdiction. 
  
 13. Reservation of Shares. The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as
will be sufficient to satisfy the requirements of the Plan. 
  
 14. Award Agreement. Awards will be evidenced by written agreements in such form as the Administrator will approve. 
  
 15. Stockholder Approval. The Plan will be subject to approval by the stockholders of the Company. Such stockholder approval will be
obtained in the degree and manner required under Applicable Laws. 
  

 7Commercial license agreement between the registrant and IRM, LLC

 [CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED
SEPARATELY WITH THE COMMISSION.] 
  
 Exhibit 10.17

  
 COMMERCIAL LICENSE AGREEMENT 
  
 This Agreement (the “Agreement”) effective as of July 12, 2000 (the
“Effective Date”) is made by and between Xenogen Corporation, having a principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and IRM, LLC, a Delaware Corporation, (“IRM”), having a
principal place of business at Sofia House, 48 Church Street, Hamilton, Bermuda. 
  
 BACKGROUND 
  
 A. Xenogen has
expertise in the development and detection of living cells, organisms and transgenic animals that have the property of bioluminescence, and owns or has rights to intellectual property relating thereto. 
  
 B. IRM wishes to obtain a non-exclusive commercial license to the Xenogen
Technology for use in the Field at the Authorized Sites (capitalized terms defined below). 
  
 NOW, therefore, the parties agree as follows: 
  
 1. Definitions. 
  
 “Xenogen Monitoring
Technology” means (i) U.S. Patent No. 5,650,135; (ii) all divisions, substitutions, continuations, and continuation-in-part applications of (i); (iii) all foreign counterparts of any of the preceding; and (iv) all patents issuing on any of the
preceding, including reissues, reexaminations and extensions; which patents and applications have been licensed to Xenogen pursuant to that certain exclusive license agreement between Xenogen and The Board of Trustees of the Leland Stanford Junior
University (“Stanford”) effective July 1,1997. 
  
 “Xenogen Technology” means (i) all patents and patent applications owned or controlled by Xenogen that relate to the practice of in vivo imaging; (ii) all divisions, substitutions, continuations, and continuation-in-part
applications of (i); (iii) all foreign counterparts of any of the preceding; (iv) all patents issuing on any of the preceding, including reissues, reexaminations and extensions; and (v) all future patents and patent applications relating to the
practice of in vivo imaging. Xenogen Technology includes the Xenogen Monitoring Technology. 
  
 “Field” means the activities specified in Exhibit A attached hereto. 
  
 “Authorized Site(s)” means the physical location(s) specified in Exhibit B attached hereto. 
  
 “Affiliate” means Novartis Pharmaceuticals Corporation
(“Novartis”) or any corporation, firm, partnership or other legal entity which, directly or indirectly, controls, is controlled by or is under common control by or with Novartis. For the purposes of this definition, “control”
shall mean the direct or indirect ownership of more than 50% of the outstanding voting securities or capital stock of such entity or any other comparable equity or ownership interest. 
  
 “System” means an imaging system as specified in Exhibit C attached hereto. 
  

 1 

 “Permitted Users” shall mean IRM, Novartis, Novartis Research Foundation, the Novartis
Institute for Functional Genomics Inc., the Friedrich Miescher Institute and all Novartis Affiliates. 
  
 “Commercial Use License” means a license by Xenogen granting rights to any for-profit entity to use the Xenogen Monitoring Technology for
commercial drug-development (e.g., compound screening and/or target validation) purposes. It is agreed that the following types of licenses do not constitute a Commercial Use License: (i) an evaluation license granted for the purpose of evaluating
Xenogen’s technology and/or BiowareTM
organisms, such as the September 1998 agreement between the parties executed by Novartis Pharmaceuticals Corporation on September 18, 1998, and by Xenogen on September 25, 1998; (ii) a strain development or modification agreement, whereby a third
party is licensed to use the Xenogen Monitoring Technology to develop new BiowareTM organisms or improve existing BiowareTM organisms, without rights to use such BiowareTM organisms for its own or contract research drug development purposes; and (iii) a distribution agreement, whereby a third party is granted rights to use the Xenogen Monitoring Technology in connection with the
distribution certain Xenogen BiowareTM organisms or
animals to third parties, without rights to use such BiowareTM organisms or animals for its own or contract research drug development purposes. 
  
 2. License Grant. 
  
 2.1 License. Xenogen hereby grants to IRM and Permitted Users, a non-exclusive, non-transferable license, without right to grant or authorize any
sublicenses, to use the Xenogen Technology solely in the Field solely at the Authorized Sites. 
  
 2.2 No Implied Rights: Retained Rights. Only the License granted pursuant to the express terms of this Agreement shall be of any legal force or effect. No other license rights shall be granted or created by
implication, estoppel or otherwise. Xenogen reserves the right to license the Xenogen Technology to others, and to use the Xenogen Technology for its own purposes. 
  
 2.3 No Warranty. IRM ACKNOWLEDGES THAT NEITHER XENOGEN NOR STANFORD MAKE ANY REPRESENTATIONS OR EXTEND ANY WARRANTIES
OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THE XENOGEN TECHNOLOGY, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE XENOGEN TECHNOLOGY WILL NOT INFRINGE THE INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES. 
  
 3. Light-Emitting Organisms. 
  
 3.1 Source. IRM and Permitted Users may develop or otherwise acquire
from any source, light-emitting organisms for use in the practice of the License. 
  
 3.2 Existing Xenogen BiowareTM Organisms. IRM and Permitted Users may license or purchase from Xenogen any BiowareTM organisms that Xenogen has available for third party licensing or purchase, respectively, at the then current list price for such BiowareTM organisms; *** 
  
 *** Confidential Treatment Requested 
  

 2 

 3.3 Custom Xenogen BiowareTM Organisms. The parties may agree to have Xenogen develop custom BiowareTM organisms for IRM or Permitted Users on terms and conditions to be negotiated in good
faith. 
  
 4. CCD Imaging System 
  
 4.1 Available Systems. Xenogen shall offer for sale or lease to IRM
and Permitted Users the Systems specified in Exhibit C, on terms and conditions to be agreed upon by the parties. 
  
 4.2 Lease. IRM and Permitted Users may lease either of the Systems specified in Exhibit C at a cost of *** per month per System. The lease price
includes on-site installation and the cost of service reasonably necessary to maintain the leased System in proper operating condition. 
  
 4.3 Purchase. IRM and permitted Users may purchase either of the Systems specified in Exhibit C at a per-System cost of *** (Hamamatsu) or ***
(IVISTM). The purchase cost of each System includes
on-site installation and one year of service and maintenance at no additional charge. 
  
 4.4 Hardware Upgrades. Xenogen shall notify IRM or Permitted Users if additional hardware with enhanced functionality for in vivo imaging (“Hardware Upgrade”) becomes available from Xenogen. At
IRM’s or Permitted Users’ option, the parties shall then negotiate in good faith the terms on which such a Hardware Upgrade could be made available to IRM or Permitted Users. *** 
  
 4.5 Service Agreement. Xenogen will make available to IRM and
Permitted Users a service agreement on terms consistent with industry norms (including standard FTE labor and parts charges and travel expenses) to provide for the service and maintenance of any System(s) purchased by IRM or Permitted Users after
expiration of the one year free service. Service will be initiated at IRM’s or Permitted Users’ request, on terms and conditions to be agreed upon by the parties. 
  
 4.6 Software License. Contingent upon the lease or purchase of at least one System by IRM or Permitted Users, Xenogen
shall grant to IRM and Permitted Users a nonexclusive, nontransferable license to use and display the Software with the Equipment and with up to five (5) additional desktop computers (per System leased or purchased) used for analysis of data
obtained using the System at the Authorized Sites for the duration of this Agreement. 
  
 4.7 Software Upgrades. Xenogen will provide to IRM and Permitted Users, without charge, any upgrades to the Software (“Software Upgrades”) that Xenogen makes available to third parties. 
  
 4.8 New Software. If Xenogen makes available to third parties any new
software suitable for use with in vivo imaging (“New Software”), Xenogen shall make the New Software available to IRM and Permitted Users on terms and conditions at least as favorable as the terms and conditions agreed to by any
commercial entity that has in place a Commercial Use License to the 
  
 ***
Confidential Treatment Requested 
  

 3 

 
Xenogen Monitoring Technology, for similar quantities of New Software within six (6) months of when the New Software becomes available to IRM and Permitted
Users. 
  
 4.9 Acknowledgement. The copyright of the
Software is and shall remain owned by Xenogen, and IRM and Permitted Users agree that they will not, without Xenogen’s prior written consent, directly or indirectly, modify, make derivative works of, or make any copies of the Software, except
those copies necessary to run the software pursuant to Section 4.6 herein. IRM and Permitted Users further agree that they shall not, directly or indirectly, attempt to reverse engineer or decompile the Software or otherwise derive source code from
the Software. 
  
 4.10 Limited Warranty. Xenogen warrants
that any System leased or purchased from Xenogen by Novartis will include all components necessary for conducting in vivo imaging experiments. 
  
 4.11 Disclaimer of All Other Warranties. XENOGEN’S LIMITED WARRANTY SET FORTH IN SECTION 4.10 IS THE EXCLUSIVE WARRANTY, AND XENOGEN MAKES NO
OTHER WARRANTIES (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE SYSTEM TRANSFERRED HEREUNDER, AND SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ALL WARRANTIES OF
NONINFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 
  
 5. Consideration. In consideration for the License provided to IRM herein, IRM shall pay to Xenogen by wire transfer to an account designated by Xenogen a fee (“Fee”) of two (2) million U.S. dollars (U.S. $2,000,000.00) per
year for each of three (3) years. Such payments will be due within fifteen (15) business days of each yearly anniversary of the Effective Date. The first payment shall be due within fifteen (15) business days of the Effective Date. 
  
 6. Ownership of Intellectual Property. IRM and Permitted Users agree
that all intellectual property rights relating to the Xenogen Monitoring Technology, the System(s) and their uses are and shall be owned or controlled exclusively by Xenogen. Xenogen agrees that all invention(s) made by IRM or the Permitted Users in
connection with the License granted hereunder that relate to subject matter other than the Xenogen Monitoring Technology, the System, or their uses shall be owned exclusively by IRM or Novartis. 
  
 7. Confidentiality. 
  
 7.1 Confidential Information. Except as expressly provided herein, the parties agree that, for the term of this
Agreement and for three (3) years thereafter, the receiving party shall protect from disclosure and shall not use for any purpose except for the purposes contemplated by this Agreement, any information identified as confidential (“Confidential
Information”) furnished to it by the disclosing party hereto. The receiving party shall use the same standard of care in safeguarding the disclosing party’s information as the receiving party uses for its own similarly sensitive
information. Confidential Information shall not include information which the receiving party shows: 
  
 (a) was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure; 
  

 4 

 (b) was generally available to the public or otherwise part of the public domain at the
time of its disclosure to the receiving party; 
  
 (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of this Agreement; 
  
 (d) was subsequently lawfully disclosed to the receiving
party by a person other than a party hereto; or 
  
 (e) was approved for release by written authorization of the disclosing party. 
  
 7.2 Permitted Use and Disclosures. Each party hereto may use or disclose information disclosed to it by the other party to the extent such use or disclosure is reasonably necessary in complying with applicable
law, legal process or governmental regulations, or exercising its rights hereunder, provided that if a party is required to make any such disclosure of another party’s Confidential Information, it will give reasonable advance notice to the
latter party of such disclosure and will use its best efforts to secure confidential treatment of such information prior to its disclosure (whether through protective order or otherwise). 
  
 7.3 Confidential Terms. Except as expressly provided herein, each party agrees not to disclose any terms of this
Agreement to any third party without the consent of the other party; provided, disclosures may be made to actual or prospective corporate partners or investors, or to a party’s accountants, attorneys and other professional advisors. Any
disclosures made to actual or prospective corporate partners or investors, or to a party’s accountants, attorneys and other professional advisors, shall be limited to statements of fact and shall not imply endorsement of the other party’s
products or services. 
  
 8. Press Release. Xenogen may make a press
release in the form attached as Exhibit D to announce the execution of this Agreement; thereafter, Xenogen and IRM may each disclose to third parties the information contained in such press release without the need for further approval by the other
party. Other press releases of any kind by either party will be released only after both parties have agreed in writing to the contents of the press releases. 
  

9. Warranties and Indemnification 
  
 9.1 Warranty of Right to Grant License. Xenogen warrants that as of the Effective Date, (a) it has the legal right to grant the License herein, and
(b) the grant of the License does not conflict with, violate, or constitute a breach or default under any contract or other obligation of Xenogen. 
  
 9.2 Warranty of Full Disclosure. Xenogen warrants that as of the Effective Date, all non-cumulative material, prior art references and information
that Xenogen is aware of and that could adversely affect Xenogen’s pending patent applications and issued patents relating to the Xenogen Monitoring Technology are presently before the United States Patent and Trademark Office (USPTO).

  
 9.3 Indemnification. (a) IRM agrees to indemnify,
defend and hold Xenogen and its directors, officers, employees and agents and The Trustees of the Leland Stanford Junior 

  

 5 

 
University, Stanford Health Services and their respective trustees, officers, employees, students and agents (the “Xenogen Indemnitee(s)”) harmless
from and against any and all liabilities, claims, demands, expenses (including, without limitation, reasonable attorneys and professional fees and other costs of litigation), losses or causes of action (each, a “Xenogen Liability”) that
may be brought against the Xenogen Indemnitee(s) by reason or arising out of or relating in any way to (i) IRM’s or Permitted Users’ possession and use of the System, whether based on negligence, product liability or otherwise, (ii) the
exercise of any right granted to IRM or Permitted Users pursuant to this Agreement, or (iii) any material breach of this Agreement by IRM or Permitted Users, except to the extent, in each case, that such Xenogen Liability is caused by the negligence
or willful misconduct by Xenogen as determined by a court of competent jurisdiction. Notwithstanding the above, neither IRM nor any Permitted User shall enter into any settlement or other agreement which makes any admission of negligence or
wrongdoing on the part of any Xenogen Indemnitee or that relates to the validity or enforceability of any patents owned by Xenogen without the prior written consent of Xenogen, which consent shall not be unreasonably withheld. (b) Xenogen agrees to
defend, indemnify and hold IRM, the Permitted Users and its directors, officers, employees, agents and assigns (the “IRM Indemnitee(s)”) harmless against any and all liabilities, claims, demands, expenses (including, without limitation,
reasonable attorney’s and professional fees and other costs of litigation), losses or causes of action (each, an “IRM Liability”) that may be brought against the IRM Indemnitee(s) by reason or arising out of or relating in any way to
any negligent act or willful misconduct on the part of Xenogen, except to the extent that such IRM Liability is caused by the negligence or willful misconduct by IRM or Permitted Users as determined by a court of competent jurisdiction.
Notwithstanding the above, Xenogen shall not enter into any settlement or other agreement which makes any admission of negligence or wrongdoing on the part of any IRM Indemnitee(s). The party seeking indemnification under this Section shall
immediately notify the other party, in writing, of any claim or proceeding brought against it for which it seeks indemnification hereunder. 
  
 10. Term and Termination 
  
 10.1 Term. This Agreement will commence on the Effective Date and unless terminated earlier as provided in this Article 10, will terminate three
(3) years after the Effective Date. 
  
 10.2 Term
Extension. Prior to the *** anniversary of the Effective Date, unless earlier terminated, IRM, Permitted Users or an assignee under Section 11.2 herein may extend the Term for up to *** additional years by paying to Xenogen a fee of *** U.S.
dollars (U.S. ***) per year of extension. 
  
 10.3 Permissive
Termination. IRM may terminate this Agreement upon thirty (30) days written notice to Xenogen for (i) failure of the Xenogen Monitoring Technology, as confirmed by at least one peer-reviewed publication by a disinterested party, (ii) a final
judgment of invalidity of all Relevant Patent Claims (as defined below) under the Xenogen Monitoring Technology, (iii) a final adverse resolution of infringement of third party intellectual property rights, or (iv) an assignment by Xenogen to a
major pharmaceutical company pursuant to Section 11.2 herein. A Relevant Patent Claim is a claim under the Xenogen Monitoring Technology that would be infringed by IRM or Permitted Users but for the License granted herein. IRM may also terminate
this Agreement after two years, and annually thereafter, for any reason with 60 days written notice prior to the annual anniversary date of this Agreement. 
  
 *** Confidential Treatment Requested 
  

 6 

 10.4 Termination for Cause. Either party may terminate this Agreement in the event the other party
has materially breached or defaulted in the performance of any of its obligations hereunder, and such default has continued for thirty (30) days after written notice thereof was provided to the breaching party by the non breaching party. Any
termination shall become effective at the end of such thirty (30) day period unless the breaching party has cured any such breach or default prior to the expiration of such period. Notwithstanding the above, in the case of a failure to pay any
amount due hereunder the period for cure of any such default following notice thereof shall be ten (10) days and, unless payment is made within such period, the termination shall become effective at the end of such period. 
  
 10.5 Automatic Termination. This Agreement shall terminate
automatically and without further notice to the other party in the event that either party shall make any unauthorized assignment for the benefit of creditors, file any petition under the bankruptcy or insolvency laws of any jurisdiction, have or
suffer a receiver or trustee to be appointed for its business or property, or be adjudicated a bankrupt or an insolvent. 
  
 10.6 Effect of Termination. 
  
 (a) Accrued Rights and Obligations. Termination of this Agreement for any reason shall not release any party hereto from any
liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination nor preclude either party from pursuing any rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement. 
  
 (b) Return of Confidential Information and Leased Systems. Upon any termination or expiration of this Agreement, IRM and Permitted Users and Xenogen shall promptly return to the other party all Confidential
Information received from the other party (except one copy which may be retained for legal archival purposes). IRM and Permitted Users shall return to Xenogen all leased Systems, including all Equipment and Software leased to IRM and Permitted Users
under any lease agreement within thirty (30) days of the termination of this Agreement. The System(s) shall be shipped to Xenogen’s facility at the address set forth in Section 11.5. IRM or Permitted Users shall pay all shipping and freight
charges, and shall assume the risk of loss during shipment. Xenogen agrees that in the event of any loss or damage to the leased System(s), IRM’s or Permitted Users’ liability for such loss or damage shall not exceed the lower of the
amortized or market values of the leased System(s) at the time of damage or loss. 
  
 (c) Licenses. The licenses granted hereunder shall terminate upon the termination of this Agreement. 
  
 10.7 Survival. Sections 2.3, 4.11, 10.6 and 10.7; and Articles 6, 7, 9
and 11 of this Agreement shall survive the expiration or termination of this Agreement for any reason. 
  
 11. Miscellaneous 
  
 11.1
Governing Law; Venue. This Agreement and any dispute, including without limitation any arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the state of
California, without reference to conflicts of laws principles. The exclusive venue of any dispute arising out of or in connection with 

  

 7 

 
the performance or breach of this Agreement shall be the California state courts or U.S. district court located in Alameda County, California. 
  
 11.2 Assignment. IRM may not transfer or assign this Agreement or any
of IRM’s rights hereunder without the written consent of Xenogen, which consent shall not be unreasonably withheld; the foregoing notwithstanding, IRM may assign this Agreement to Novartis or any Novartis Affiliate. Xenogen may assign this
Agreement or its rights hereunder. This Agreement shall be binding upon and inure to the benefit of the parties and their permitted successors and assigns. 
  
 11.3 Waiver. No waiver of any rights, shall be effective unless consented to in writing by the party to be charged and the waiver of any breach or
default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 
  
 11.4 Severability. In the event that any provision of this Agreement is determined to be invalid or unenforceable by a court of competent
jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. 
  
 11.5 Notices. All notices, requests and other communications hereunder shall be in writing and shall be personally delivered or sent by telecopy or
other electronic facsimile transmission or by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to the other parties
hereto: 
  

					
	 	 	IRM:	  	 IRM, LLC
 P. O. Box HM 2899
 Hamilton HMLX, Bermuda

			
	 	 	Xenogen:	  	 Xenogen Corporation
 860 Atlantic Avenue
 Alameda, CA 94501
 Attn: President

  
 11.6 Independent
Contractors. Both parties are independent contractors under this Agreement. Nothing contained in this Agreement is intended nor is to be construed so as to constitute Xenogen or Novartis as partners or joint venturers with respect to this
Agreement. Neither party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement, or undertaking with any
third party. 
  
 11.7 Use of Name. Neither IRM nor
Permitted Users shall use the name or trademarks of Xenogen or Stanford without the prior written consent of Xenogen or Stanford, respectively. Xenogen shall not use the name or trademarks of IRM or the Permitted Users without prior written consent,
respectively. 
  
 11.8 Compliance with Laws. In exercising
their rights under this license, the parties shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights
under this Agreement. 
  

 8 

 11.9 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL,
CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES, INCLUDING, WITHOUT LIMITATION, ANY LOSS OF USE, REVENUE OR PROFIT, ARISING OUT OF THIS AGREEMENT, THE EXECUTION OF THE LICENSE, OR ANY BREACH OR DEFAULT UNDER THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY
THEORY OF LIABILITY. 
  
 11.10 “Most Favored
Licensee”. Xenogen agrees that it will not grant, to any commercial entity, a Commercial Use License with no milestone, royalty or per-use fees, to use the Xenogen Technology for All Fields, for a per-year license fee which is less than the
per-year license fee paid by IRM under this Agreement. In the event that Xenogen does grant such a license to any other commercial entity, Xenogen will refund or credit IRM the difference. This clause shall not apply to any settlements for past
infringement. 
  
 11.11 Entire Agreement; Amendment. This
Agreement, together with its Exhibits, constitutes the entire and exclusive Agreement between the parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect
thereof. No amendment or addition to this Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the parties. 
  

									
	 IRM, LLC
	 	 	 	 XENOGEN CORPORATION

					
	Signature:	 	/s/ Dr. J. Reinhardt         /s/ Dr. B. Aebischer	 	 	 	Signature:	 	/s/ David W. Carter
	 	 	
	 	 	 	 	 	

	Printed Name:	 	Dr. J. Reinhardt              Dr. B. Aebischer	 	 	 	Printed Name:	 	David W. Carter
	Title:	 	President                         Secretary	 	 	 	Title:	 	Chairman
	Date:	 	                         7/25/2000
	 	 	 	Date:	 	7/10/00

  
 Exhibit A: Field 
 Exhibit B: Authorized Site 
 Exhibit C: CCD Imaging System 
 Exhibit D: Press Release 
  

 9 

 EXHIBIT A 
  

Field 
  
 Drug discovery, lead compound development, pre-clinical evaluation & development (including efficacy and safety assessment, such as toxicology), and clinical research & development for all targets, diseases
and indications. 
  

 EXHIBIT B 
  

Authorized Sites 
  
 All Novartis sites 
 The sites of all Novartis Affiliates 
 The Novartis Research Foundation entities including, but not limited to: 
 The Novartis Institute for Functional Genomics, and 
 The Friedrich Miescher Institute. 
  

 EXHIBIT C 
  
 CCD Imaging Systems Available for Sale or Lease to IRM or Permitted Users 
  
 Hardware 
  
 Hamamatsu 2400 Imaging System 
  

	 	•	Hamamatsu intensified CCD camera 

  

	 	•	Hamamatsu (Argus) Image Processor 

  

	 	•	Nikkor® 50 mm f 1.2 lens 

  

	 	•	Hamamatsu specimen chamber 

  

	 	•	Macintosh® control computer with high-resolution monitor 

  
 Xenogen IVISTM
Imaging System 
  

	 	•	Roper LN-1300EB cooled CCD camera (or equivalent) 

  

	 	•	Navitar 50 mm f 0.95 lens (or equivalent) 

  

	 	•	Xenogen specimen chamber 

  

	 	•	Windows 98® control computer with high-resolution monitor 

  
 Software 
  
 LivingImageTM image processing and data
analysis software 
  

 EXHIBIT D 
  

PRESS RELEASE 
  
 XENOGEN CORPORATION GRANTS NOVARTIS LICENSE TO XENOGEN’S 
 PATENTED REAL-TIME IN VIVO IMAGING TECHNOLOGY 
  
 Alameda, CA (July XX, 2000) — Xenogen Corporation, a leader and innovator in the field of real time in vivo imaging,
and a company of Novartis Research Foundation today announced they have entered into a full commercial licensing agreement for Xenogen’s real time in vivo imaging technology. This agreement grants Novartis complete access to Xenogen’s
proprietary suite of technologies for use in pre-clinical drug development studies at any Novartis site worldwide. 
  
 The three-year, multi-million dollar agreement (with an option for an additional four years) is the result of a successful pilot study with Xenogen’s
technology under an “evaluation license” during which Novartis assessed the technology’s potential in its pharmaceutical research and development process. Xenogen has a number of such evaluation license agreements with other major
pharmaceutical companies worldwide. 
  
 Xenogen’s unique and
unrivaled technology represents a novel approach to the biological assessment of new chemical entities (NCEs) — compounds that serve as the basis for new drugs. Critical advantages offered by Xenogen’s technology include providing higher
quality data at earlier time points, resulting in a better selection of drug development candidates. These advantages result in significant time and cost savings in drug development. 
  
 “Based on the success of our evaluation licensing agreement, Novartis is confident in our decision to expand our
business relationship with Xenogen,” said Alexander Wood, Ph.D., representing Novartis. “We are optimistic that Xenogen’s technology will help improve the speed, accuracy and cost-effectiveness of our pharmaceutical discovery and
development programs.” 
  
 “Xenogen is pleased to expand
its alliance with Novartis, a worldwide leader in pharmaceutical research. By applying Xenogen’s technology in a cancer model, Novartis has elegantly demonstrated the potential to expedite the development of important new drugs across the
spectrum of therapeutic areas,” said Dr. Pamela Reilly Contag, Ph.D., president and co-CEO of Xenogen Corporation. “The Novartis license represents a milestone for Xenogen in the commercialization of this valuable and unique
technology.” 

 About the Technology 
  
 Xenogen’s patented real-time in vivo imaging technology enables the detection of fluorescent or bioluminescent cells
(e.g., tumor cells and bacteria) inside intact living animals, allowing non-invasive visualization and tracking of the cells to monitor the effects of treatment with NCEs in vivo in real time. The technology also provides researchers with a way to
localize and follow the activation of selected genes in vivo in Xenogen’s LPTATM light-producing transgenic animals. 
  
 Real-time in vivo imaging offers pharmaceutical companies like Novartis a number of unique benefits to help increase the productivity of their drug
development pipelines. Compared to traditional methods the technology provides improved, more predictive data and thus a better selection process for drug development candidates. In addition, Xenogen’s technology allows researchers to conduct
assessments more rapidly and efficiently. The resulting reduction in labor costs, coupled with a reduction in the number of test animals needed, leads to significant overall cost savings. 
  
 Novartis 
  
 Novartis researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including
central nervous system disorders, organ transplantation, cardiovascular diseases, dermatological diseases, respiratory disorders, cancer and arthritis. The company’s mission is to improve people’s lives by pioneering novel healthcare
solutions. 
  
 Located in East Hanover, New Jersey, Novartis
Pharmaceuticals Corporation is an affiliate of Novartis AG, a world leader in healthcare with core businesses in Pharmaceuticals, consumer health, generics, eye-care, and animal health. In 1999, the Group (including agribusiness) achieved sales of
USD 21.7 billion and invested more than USD 2.8 billion in R&D. Headquartered in Basel, Switzerland, Novartis employs about 82,400 people and operates in over 140 countries around the world. The Group recently announced plans to spin off its
crop protection and seeds sectors and to merge them with the agrochemicals business of AstraZeneca in the second half of 2000. 

 Xenogen Corporation 
  
 Xenogen Corporation is a leader in the field of real-time in vivo imaging, providing the pharmaceutical industry with
proprietary technologies, products and services that enable real-time in vivo monitoring to rapidly identify drug leads for successful clinical development. These technologies, unique to Xenogen, enable researchers to overcome barriers that have
complicated NCE assessment for many years. 
  
 Xenogen’s
technology has attracted strong interest from a wide range of pharmaceutical companies worldwide. In addition to pharmaceutical development, the technology has broad applications in other fields, including toxicology and the chemical industry.

 AMENDMENT TO COMMERCIAL LICENSE AGREEMENT 
  
 THIS AMENDMENT, effective as of July 12, 2003, (the “Effective Date”), is made by and between Xenogen Corporation, having
principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation having a principal place of business at 400 Technology Square,
Cambridge, Massachusetts 02139 (“NIBRI”). 
  
 WITNESSETH

  
 WHEREAS, Xenogen and IRM, LLC, a Delaware corporation, are parties to a
Commercial License Agreement, effective as of July 12, 2000 (the “License Agreement”); 
  
 WHEREAS, NIBRI is an “Affiliate” of IRM and a “Permitted User” under the License Agreement, as the terms “Affiliate” and “Permitted User” are defined in the License Agreement;

  
 WHEREAS, NIBRI has the right under section 10.2 of the License Agreement to
extend the term of the license agreement for up to four additional years by payment of a specified fee; 
  
 WHEREAS, NIBRI wishes to extend the License Agreement for two additional years and Xenogen and NIBRI have agreed upon a fee and payment schedule for such additional years that are different from those provided for in
the License Agreement; and 
  
 WHEREAS, the parties wish to amend certain other
terms and provisions of the License Agreement; 
  
 NOW, THEREFORE, the parties
agree as follows: 
  

	 	1.	Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. 

  

	 	2.	The Term of the License Agreement is hereby extended for two years beginning upon the Effective Date of this Amendment (the “Extension Term”). 

  

	 	3.	NIBRI or an Affiliate will pay to Xenogen a fee of *** for the Extension Term. Such fee will be due 60 days after the Effective Date. The payment of such fee by NIBRI or an
Affiliate shall be in lieu of the payment of fees by IRM for the Extension Term. 

  

	 	4.	Prior to the end of the Extension Term, unless earlier terminated, IRM, Permitted Users or an assignee under section 11.2 of the License Agreement may extend the Extension Term for
up to two additional years by paying to Xenogen a fee of $1,500,000 per year of extension. 

  

	***	Confidential Treatment Requested 

	 	5.	Section 11.10 of the License Agreement is hereby amended to read as follows: 

  

11.10 “Most Favored Licensee”. Xenogen agrees that if it grants to any pharmaceutical or biotechnology company that is among the 20
largest pharmaceutical and biotechnology companies in the world, measured by either market capitalization or annual sales, a Commercial Use License with no milestone, royalty or per-use fees, to use the Xenogen Technology for All Fields, for a
per-year license fee which is less than the per-year license fee paid by IRM under this Agreement (as amended effective July 12, 2003), then Xenogen shall refund or credit IRM the difference between such license fee paid by IRM and such lower
license fee paid by such other company. This clause shall not apply to any settlements for past infringement. 
  

	 	6.	The first sentence of the definition of Commercial Use License in Section 1 of the License Agreement is amended to read as follows: 

  
 “Commercial Use License” means an enterprise-wide, unlimited use
license by Xenogen granting rights to any for-profit entity to use the Xenogen Monitoring Technology for commercial drug-development (e.g., compound screening and/or target validation) purposes.” 
  

	 	7.	Sections 4.1 through 4.3 of the License Agreement are hereby deleted and replaced with the following: 

  
 “4.1 Xenogen will make available its IVIS® Imaging System 100 available for purchase by IRM or Permitted Users for *** during calendar year 2003 and for *** for
the remaining term of this Agreement.” 
  
 The remaining
subsections 4.4 through 4.11 of the License Agreement are renumbered 4.2 through 4.9. 
  

	 	8.	Except as amended hereby, the License Agreement shall remain in full force and effect, according to its terms. 

  

	 	9.	This Amendment, and the License Agreement as amended, shall constitute the entire agreement between the parties and shall supersede all other agreements, whether written or oral,
relating to the subject matter hereof. 

	***	Confidential Treatment Requested 

 IN WITNESS WHEREOF, the parties have entered into this Amendment effective as of July 12, 2003, by signatures of their
duly authorized officers set forth below. 
  
 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 
  

			
	By:	 	 [Signature Illegible]

		
	 Title:
	 	 VICE PRESIDENT

  
 XENOGEN CORPORATION 
  

			
	By:	 	 /s/    David W. Carter

		
	 Title:
	 	 CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]